A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose ASA and Metformin in Stage I-III Crc Patients
Key facts
- Who runs it
- Ente Ospedaliero Ospedali Galliera
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 160 people enrolled
- Started
- 15 Mar 2017
- Ended
- 31 Mar 2024
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- ASA
- MET
- Placebo
- Record updated
- 27 January 2025
- Why it stopped
- lack of enrolment
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Patients aged > 18 and ≤ 80 years
- Patients with completely resected stage I, II, or III primary colorectal cancer within 24 months prior to randomization, regardless of (neo-)adjuvant chemotherapy. Patients with pT1 CRC treated with endoscopic polypectomy
- Adjuvant chemotherapy and (neo-)adjuvant radiotherapy terminated at least 3 months before randomization
- ECOG performance status ≤ 1
- Satisfactory hematological and biochemical functions:; Platelets ≥ 100 x 10\^9/L; Creatinine clearance estimated with the Cockcroft - Gault formula ≥ 60 mL/min. Patients with Gault formula ≥ 45-59 ≤ ml/min are eligible but they will receive a single (evening) tablet of MET, 850 mg; AST and ALT ≤ 2.5 times ULN
- Females of childbearing potential/males with partners of childbearing potential participating in the study are to use effective methods of birth control during study participation. Female participants must provide a pregnancy test, according to local/national guidelines
- Able to understand and sign an informed consent (or have a legal representative who is able and willing to do so)
Who cannot take part
- Chronic treatment with ASA or other NSAIDs or MET or patients who are on current long term treatment (≥ 4 consecutive weeks) with ASA, NSAID or COX -2 inhibitors or MET
- Diabetic patients on drug treatment are excluded
- Anticoagulant therapy (dicumarol, heparin, fondaparinux, apixaban, dabigatran etexilate, rivaroxaban) or active current treatment with antiplatelet agents (e.g. off-study ASA, clopidogrel, prasugrel, ticagrelor, or ticlopidine)
- Alcohol or drug abuse
- Prior history of gastro-intestinal bleeding or hemorrhagic diathesis (e.g. hemophilia)
- Concomitant corticosteroid treatment
- Treatment with another investigational drug < 28 days prior to study entry
- Concurrent participation in a clinical trial with the same endpoints
- Patients who are allergic or intolerant to ibuprofen or naproxen,or who have MET-, or ASA-, or salicylate intolerance or more generalized drug intolerance to non-steroidal anti-inflammatory drugs (NSAIDs)
- Any other invasive malignancies (with the exclusion of basal cell carcinoma or cutaneous squamous cell carcinoma) diagnosed during the last 5 years before randomization. Past history of any other invasive CRC than the one the patient is currently being treated for
- History of erosive GERD or active erosive GERD on gastroscopy
- History of hemorrhagic stroke
- Lynch Syndrome (HNPCC)
- Crohn's disease (CD) and Ulcerative Colitis (UC)
- History of lactic acidosis
- Liver dysfunction including chronic active hepatitis and cirrhosis not compensated
- History of vitamin B12 deficiency or megaloblastic anemia
- Uncontrolled coronary syndrome or symptomatic congestive heart failure (e.g. Class III or IV New York Heart Association's Functional Classification)
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing or participating in the study and/or comply with study procedures
- Known deficiency of glucose-6-phosphate dehydrogenase (G6PD)
- Patients who are not able to undergo colonoscopy
- Erosive-ulcerative lesions in the gastrointestinal tract
- Pregnant or lactating females
- Inability or unwillingness to swallow tablets
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
It has been shown that Aspirin (ASA) as well as Metformin (Met) can inhibit the incidence and mortality of colorectal cancer (CRC). In this randomized, placebo controlled clinical trial we compare the effect of these two drugs alone and their combination to prevent recurrent CRC after surgery.
The 4 groups in the trial
- PlaceboPlacebo, for comparison
placebo Aspirin (1 tablet daily) + placebo Metformin (1 tablet BID) for 12 months
- MetforminTreatment being tested
placebo Aspirin (1 tablet daily) + active Metformin (850 mg, 1 tablet BID), for 12 months
Treatment: MET
- AspirinTreatment being tested
active Aspirin (100 mg, 1 tablet daily) + placebo Metformin (1 tablet BID), for 12 months
Treatment: ASA
- Apirin plus MetforminTreatment being tested
active Asprin (100 mg, 1 tablet daily) + active Metformin (850 mg, 1 tablet BID), for 12 months
Treatment: ASA and MET
Results explained
A paper that names this trial, explained in plain words.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Phase II, Double-blind, Placebo-controlled, Multicenter, 2x2 Factorial Design Biomarker Tertiary Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients. the ASAMET Trial
- Publications
- Biomarker Modulation by Aspirin and Metformin for Colorectal Cancer Prevention: Results from the ASAMET Randomized Phase II Trial.Cancer research communications, 2026
- The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.BMC cancer, 2018
- Record updated
- 27 January 2025